The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Familial Chylomicronemia Syndrome
Hyperlipoproteinemia Type I
Syndrome

Clinical Trial Details

NCT number	NCT02211209
Study type	Interventional
Source	Ionis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	December 2014
Completion date	March 28, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04223908` - InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia
Active, not recruiting	`NCT05130450` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)	Phase 3
Completed	`NCT04568434` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)	Phase 3
Completed	`NCT03912181` - Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes
Not yet recruiting	`NCT05902598` - A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome	Phase 3
Active, not recruiting	`NCT05185843` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen	Phase 3
Completed	`NCT02658175` - The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome	Phase 3
Completed	`NCT03360747` - Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)	Phase 2
Available	`NCT06360237` - Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)